Nektar TherapeuticsNKTRNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-9.4%
5Y CAGR-8.1%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-9.4%/yr
vs +3.2%/yr prior
5Y CAGR
-8.1%/yr
Consistent
Acceleration
-12.6pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
4 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$68.67M-10.5%
2024$76.75M-0.9%
2023$77.42M-16.2%
2022$92.33M-24.8%
2021$122.84M+17.3%
2020$104.68M+6.0%
2019$98.71M+21.2%
2018$81.44M+55.5%
2017$52.36M+18.3%
2016$44.27M-